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There is a good amount of evidence that exposure therapy is an effective treatment for posttraumatic stress
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of exposure therapy efficacy for PTSD emerged. Basic research found evidence of the pharmacological
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T
here is a good amount of evidence that (pro-
longed) exposure therapy is an effective treatment
for posttraumatic stress disorder (PTSD) (Powers,
Halpern, Ferenschak, Gillihan, & Foa, 2010). It is a
first-line treatment recommended in guidelines world-
wide. Nevertheless, not all patients benefit from exposure
therapy. Clinical trials have shown that approximately
50% of patients lose their PTSD diagnosis after exposure
therapy and that the proportion of patients achieving
complete remission is even smaller (Bradley, Greene,
Russ, Dutra, & Westen, 2005; Schnurr et al., 2007).
In an attempt to improve treatment efficacy, some
researchers added other psychological interventions to
exposure therapy, such as cognitive restructuring (Foa
et al., 2005; Resick et al., 2008) or imaginal rescripting
(Arntz, Tiesema, & Kindt, 2007). Although some studies
found support for beneficial effects, overall the effect sizes
did not exceed those of stand-alone exposure therapy in
a clinically significant way (see for review: Kehle-Forbes
et al., 2012).
Another way to improve treatment efficacy that
is commonly seen in clinical care is the combination
of exposure therapy and pharmacological treatment
such as antidepressant medication. However, controlled
studies investigating the efficacy of this combined treat-
ment strategy are scarce. Rothbaum et al. (2006) exam-
ined the effect of adding prolonged exposure (PE; Foa
& Rothbaum, 1998) for SSRI non-responders. PTSD
patients were provided with 10 weeks of open-label
sertraline and those who did not remit were then
randomized to either receive five additional weeks of
sertraline alone or with 10 sessions of twice weekly
PE. Results show that the addition of 10 sessions of PE
led to increased treatment gains but only for patients
who showed a partial response to phase I sertraline
treatment. PE augmentation was associated with lower
PTSD severity score, more remitters at 6 month follow-
up, and maintenance of treatment gains. In an almost
mirror design, no beneficial effects were found for
paroxetine enhancement when given in addition to PE
to exposure refractory patients (Simon et al., 2008). In
contrast, however, Schneier and colleagues (2012) found
that when the combination of exposure therapy and
paroxetine (an SSRI) was provided from the beginning
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of treatment, it was more effective than exposure therapy
plus placebo, implying additive benefits. However, the
additive benefits disappeared by follow-up. Even though
initial treatment with exposure therapy and paroxetine
may lead to good clinical outcome, there are also some
important disadvantages of this combination strategy,
such as adverse events of medication, higher treatment
costs, lower treatment acceptability and the risk of relapse
after medication discontinuation, as was shown with
SSRI as a stand-alone treatment for PTSD (Davidson
et al., 2001; Farach et al., 2012).
Recently, an interesting new direction in the improve-
ment of exposure therapy efficacy for PTSD emerged.
Basic research in animals found evidence of the pharma-
cological enhancement of the underlying learning and
memory processes of exposure therapy: extinction learn-
ing and reconsolidation (Debiec & Ledoux, 2004; Walker,
Ressler, Lu, & Davis, 2002). Extinction learning refers
to the process wherein a conditioned stimulus (CS; i.e.,
a trauma reminder) is repeatedly presented in absence
of the unconditioned stimulus (US; i.e., the traumatic
experience) thereby leading to reduction of the condi-
tioned response (CR; i.e., fear). It is believed that with
extinction learning a new association (CS-noUS) is
formed and consolidated, while the original fear-memory
stays intact (Bouton, 1993; LeDoux, 1995). In contrast,
reconsolidation might change the original fear memory.
Reconsolidation refers to the process wherein a pre-
viously consolidated memory (i.e., the fear memory),
enters a labile state upon its retrieval, in which it might
be susceptible to change. Even though it is not perfectly
understood if and how extinction and reconsolidation
inter-relate during exposure therapy (Kindt & Soeter,
2013), both seem to be underlying its efficacy.
Findings in basic animal research that these memory
and learning processes can be pharmacologically targeted
have been translated to studies in clinical populations (f.i.
Ressler et al., 2004). In several anxiety disorders it has
been examined whether different pharmacological agents,
often referred to as cognitive enhancers, can optimize
exposure treatment efficacy. This new line of pharmaco-
logical treatment enhancement can be distinguished from
traditional pharmacotherapy in the following ways: (1)
the pharmacological agent is always given in supplemen-
tary fashion to exposure by administration either shortly
before or after an exposure session; (2) the enhancer is
not expected to positively affect treatment outcome as
such, but to do so solely by augmentation of exposure
effects.
The aim of the current review is to give an overview
of clinical studies on pharmacological enhancement of
exposure-based treatment for PTSD. Thus far, reviews
have focused mainly on fundamental research or specific
pharmacological backgrounds (Choi, Rothbaum, Gerardi,
& Ressler, 2010; Dunlop, Mansson, & Gerardi, 2012;
Parsons & Ressler, 2013). We were more interested in
the clinical value of enhancement studies and focused
on clinical questions such as: What are the proposed
working mechanisms of different enhancers? What is
known about enhancement effects of different pharma-
cological agents in PTSD patients? What would be the
feasibility of these enhancers in clinical practice? There-
fore, we focused on describing pharmacological agents
that were studied in PTSD patients and administered
in addition to (at least one) exposure-based treatment
session, with the aim to enhance extinction or reconsoli-
dation processes. This resulted in reviewing four differ-
ent pharmacological enhancers: D-cycloserine, MDMA,
hydrocortisone, and propranolol.
D-cycloserine
Proposed working mechanism of D-cycloserine
Fear extinction has been linked to N-methyl-D-aspartate
(NMDA) glutamatergic receptor activity in the basolat-
eral amygdala (Norberg, Krystal, & Tolin, 2008). Animal
research suggested that NMDA receptor agonists, such
as the partial agonist D-cycloserine (DCS), can enhance
extinction effects (Richardson, Ledgerwood, & Cranney,
2004; Walker et al., 2002). Translating the positive
findings in animals to humans, clinical studies in diverse
anxiety-disordered clinical populations [e.g., in acropho-
bia (Ressler et al., 2004), social phobia (Hofmann et al.,
2006) and panic disorder (Otto et al., 2010)] showed
that fear extinction is indeed facilitated by supple-
menting exposure therapy with DCS (see for review:
Bontempo, Panza, & Bloch, 2012; Norberg et al., 2008).
The beneficial effects of DCS are attributable to extinc-
tion enhancement and not to anxiolytic effects of the
drug, since both animal and human studies showed that
fear expression (i.e., freezing in animals and subjective
fear in humans) during extinction/exposure is not influ-
enced by DCS (Kushner et al., 2007; Ressler et al., 2004;
Walker et al., 2002).
DCS enhancement of exposure-based treatment
in PTSD patients
To date, two studies examined the additional effect
on DCS in PE therapy for PTSD. De Kleine, Hendriks,
Kusters, Broekman, and van Minnen (2012) investigated
the effect of DCS in a mostly women, mixed-trauma
civilian sample. Sixty-seven participants were randomized
to receive either DCS (50 mg, N34, see Table 1) or
identical looking placebo (N33) 1 hour prior to each
imaginal exposure session (max. nine enhanced sessions).
Exposure therapy was delivered in adherence to the
PE manual (Foa & Rothbaum, 1998), and this included
imaginal exposure therapy sessions that were enhanced
with DCS. Overall, no enhancement effects of DCS were
found: irrespective of treatment condition, symptoms
Rianne A. de Kleine et al.
2
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2013, 4: 21626 - http://dx.doi.org/10.3402/ejpt.v4i0.21626
T
ab
le
1
.
C
h
a
ra
ct
er
is
ti
cs
a
n
d
o
u
tc
o
m
e
o
f
re
v
ie
w
ed
en
h
a
n
ce
m
en
t
st
u
d
ie
s
A
u
th
o
r
(y
e
a
r)
C
o
g
n
it
iv
e
e
n
h
a
n
c
e
r
P
o
p
u
la
ti
o
n
S
tu
d
y
d
e
s
ig
n
In
te
rv
e
n
ti
o
n
O
u
tc
o
m
e
(C
A
P
S
)
O
th
e
r
o
u
tc
o
m
e
m
e
a
s
u
re
C
o
m
m
e
n
ts
D
e
K
le
in
e
e
t
a
l.
2
0
1
2
D
C
S
C
iv
ili
a
n
,
7
9
%
w
o
m
e
n
,
m
ix
e
d
tr
a
u
m
a
,
N

6
7
R
C
T;
5
0
m
g
D
C
S
o
r
p
la
c
e
b
o
6
0
m
in
u
te
s
p
ri
o
r
to
(m
a
x
)
9
p
ro
lo
n
g
e
d
e
x
p
o
s
u
re
s
e
s
si
o
n
s
P
ro
lo
n
g
e
d
e
x
p
o
s
u
re
;
im
a
g
in
a
l
e
x
p
o
s
u
re
(3
0
4
5
m
in
u
te
s
)
&
e
x
p
o
s
u
re
in
v
iv
o
;
h
o
m
e
w
o
rk
a
s
s
ig
n
m
e
n
ts
;
1
p
s
yc
h
o
-
e
d
u
c
a
ti
o
n
a
n
d
9
e
x
p
o
s
u
re
s
e
s
si
o
n
s
.
N
o
s
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
ts
.
P
re
tr
e
a
tm
e
n
t:
D
C
S
:
6
1
.8
P
la
c
e
b
o
:
7
3
.8
P
o
st
tr
e
a
tm
e
n
t
(in
te
n
t-
to
-t
re
a
t;
m
o
d
e
l
m
e
a
n
s)
:
D
C
S
:
3
4
.3
P
la
c
e
b
o
:
5
3
.7
S
e
lf
-r
e
p
o
rt
(P
S
S
-S
R
):
n
o
ti
m
e

g
ro
u
p
d
iff
e
re
n
c
e
s
.
L
it
z e
t
a
l.
2
0
1
2
D
C
S
V
e
te
ra
n
,
m
a
le
,
N

2
6
R
C
T;
5
0
m
g
D
C
S
o
r
p
la
c
e
b
o
3
0
m
in
u
te
s
p
ri
o
r
to
4
e
x
p
o
s
u
re
s
e
s
s
io
n
s
B
ri
e
f
e
x
p
o
s
u
re
th
e
ra
p
y
;
Im
a
g
in
a
l
e
x
p
o
s
u
re
(5
0
m
in
u
te
s
);
1
p
s
y
c
h
o
-
e
d
u
c
a
ti
o
n
,
4
e
x
p
o
s
u
re
a
n
d
1
re
la
p
s
e
p
re
v
e
n
ti
o
n
s
e
s
si
o
n
.
S
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
t,
in
fa
v
o
r
o
f
p
la
c
e
b
o
.
P
re
tr
e
a
tm
e
n
t:
D
C
S
:
6
9
.9
P
la
c
e
b
o
:
7
3
.4
P
o
st
tr
e
a
tm
e
n
t
(in
te
n
t-
to
-t
re
a
t)
:
D
C
S
:
7
2
.3
P
la
c
e
b
o
:
5
3
.7
S
e
lf
-r
e
p
o
rt
(P
C
L
):
s
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
t,
in
fa
v
o
r
o
f
p
la
c
e
b
o
.
B
o
u
so
,
D
o
b
lin
,
F
a
rr
e
,
A
lc
a
za
r,
&
G
o
m
e
z-
J
a
ra
b
o
,
2
0
0
8
M
D
M
A
C
iv
ili
a
n
,
w
o
m
e
n
,
s
e
x
u
a
l
a
s
s
a
u
lt
,
N

6
R
C
T;
5
0
m
g
M
D
M
A
,
7
5
m
g
M
D
M
A
o
r
p
la
c
e
b
o
p
ri
o
r
to
1
e
x
p
e
ri
m
e
n
ta
l
s
e
s
si
o
n
C
o
n
fr
o
n
ta
ti
o
n
w
it
h
th
e
tr
a
u
m
a
ti
c
e
v
e
n
t,
d
is
c
u
s
s
io
n
o
f
n
a
rr
a
ti
v
e
a
n
d
n
e
w
in
s
ig
h
ts
,
e
x
p
e
ri
e
n
c
e
-b
a
s
e
d
(6
h
o
u
rs
);
1
s
e
s
si
o
n
N
o
re
s
u
lt
s
a
v
a
ila
b
le
M
it
h
o
e
fe
r
e
t
a
l.
2
0
1
1
M
D
M
A
C
iv
ili
a
n
,
8
5
%
w
o
m
e
n
,
m
ix
e
d
tr
a
u
m
a
,
N

2
0
R
C
T;
1
2
5
m
g
(
6
2
.5
m
g
)
M
D
M
A
o
r
p
la
c
e
b
o
p
ri
o
r
to
2
e
x
p
o
s
u
re
-b
a
se
d
s
e
s
si
o
n
s
R
e
la
x
a
ti
o
n
,
e
x
p
e
ri
e
n
c
e
-b
a
se
d
,
in
tr
o
s
p
e
c
ti
o
n
a
n
d
d
is
c
u
s
s
io
n
o
f
e
x
p
e
ri
e
n
c
e
s
(8
1
0
h
o
u
rs
);
2
in
tr
o
d
u
c
to
ry
s
e
s
si
o
n
s,
2
M
D
M
A
/p
la
c
e
b
o
e
n
h
a
n
c
e
d
s
e
s
si
o
n
s
,
4
in
te
g
ra
ti
o
n
s
e
s
si
o
n
s
a
ft
e
r
e
a
c
h
e
n
h
a
n
c
e
d
s
e
s
si
o
n
(8
in
to
ta
l).
*
S
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
t,
in
fa
v
o
r
o
f
M
D
M
A
.
P
re
tr
e
a
tm
e
n
t:
M
D
M
A
:
7
9
.2
P
la
c
e
b
o
:
7
9
.6
P
o
st
tr
e
a
tm
e
n
t:
M
D
M
A
:
2
9
.3
P
la
c
e
b
o
:
6
6
.8
S
e
lf
-r
e
p
o
rt
(I
E
S
-R
):
S
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
t,
in
fa
v
o
r
o
f
M
D
M
A
.
R
e
su
lt
s
w
e
re
m
a
in
ta
in
e
d
a
t
fo
llo
w
-u
p
(M
it
h
o
e
fe
r
e
t
a
l.,
2
0
1
3
)
O
e
h
e
n
e
t
a
l.
2
0
1
3
M
D
M
A
C
iv
ili
a
n
,
8
3
%
w
o
m
e
n
,
m
ix
e
d
tr
a
u
m
a
,
N

1
2
R
C
T;
1
2
5
m
g

6
2
.5
m
g
M
D
M
A
o
r
a
c
ti
ve
p
la
c
e
b
o
2
5

1
2
.5
m
g
M
D
M
A
R
e
la
x
a
ti
o
n
,
e
x
p
e
ri
e
n
c
e
-
b
a
s
e
d
,
in
tr
o
s
p
e
c
ti
o
n
a
n
d
d
is
c
u
s
s
io
n
o
f
e
x
p
e
ri
e
n
c
e
s
(8
1
0
h
o
u
rs
);
2
N
o
s
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
t.
P
re
tr
e
a
tm
e
n
t:
M
D
M
A
:
6
6
.4
S
e
lf
-r
e
p
o
rt
(I
E
S
-R
):
s
ig
n
if
ic
a
n
t
ti
m
e

g
ro
u
p
e
ff
e
c
t,
in
fa
v
o
r
o
f
M
D
M
A
.
Exposure enhancement in PTSD patients
Citation: European Journal of Psychotraumatology 2013, 4: 21626 - http://dx.doi.org/10.3402/ejpt.v4i0.21626 3
(page number not for citation purpose)
T
a
b
le
1
(C
o
n
ti
n
u
e
d
)
A
u
th
o
r
(y
e
a
r)
C
o
g
n
it
iv
e
e
n
h
a
n
c
e
r
P
o
p
u
la
ti
o
n
S
tu
d
y
d
e
s
ig
n
In
te
rv
e
n
ti
o
n
O
u
tc
o
m
e
(C
A
P
S
)
O
th
e
r
o
u
tc
o
m
e
m
e
a
s
u
re
C
o
m
m
e
n
ts
p
ri
o
r
to
3
e
x
p
o
s
u
re
-
b
a
s
e
d
s
e
s
s
io
n
s
in
tr
o
d
u
c
to
ry
s
e
s
si
o
n
s;
3
M
D
M
A
/a
c
ti
v
e
p
la
c
e
b
o
e
n
h
a
n
c
e
d
s
e
s
si
o
n
s
,
3
in
te
g
ra
ti
o
n
s
e
s
si
o
n
s
a
ft
e
r
e
a
c
h
e
n
h
a
n
c
e
d
s
e
s
si
o
n
(9
in
to
ta
l).
P
la
c
e
b
o
:
6
3
.4
P
o
st
tr
e
a
tm
e
n
t:
M
D
M
A
:
5
0
.8
P
la
c
e
b
o
:
6
6
.5
B
ru
n
e
t
e
t
a
l.
2
0
0
8
P
ro
p
ra
n
o
lo
l
C
iv
ili
a
n
,
5
2
%
w
o
m
e
n
,
m
ix
e
d
tr
a
u
m
a
,
N

1
9
R
C
T;
4
0
m
g
s
h
o
rt
-
a
c
ti
n
g

6
0
m
g
lo
n
g
-
a
c
ti
n
g
p
ro
p
ra
n
o
lo
l;
im
m
e
d
ia
te
ly
a
ft
e
r
1
tr
a
u
m
a
ti
c
re
a
c
ti
v
a
ti
o
n
s
e
s
si
o
n
Tr
a
u
m
a
ti
c
m
e
m
o
ry
re
a
c
ti
v
a
ti
o
n
;
w
ri
tt
e
n
d
e
s
c
ri
p
ti
o
n
o
f
in
d
e
x
tr
a
u
m
a
(2
0
m
in
u
te
s
);
1
s
e
s
si
o
n
.
N
/A
P
h
y
s
io
lo
g
ic
a
l
o
u
tc
o
m
e
:
lo
w
e
r
h
e
a
rt
ra
te
a
n
d
s
k
in
c
o
n
d
u
c
ta
n
c
e
in
re
s
p
o
n
s
e
to
tr
a
u
m
a
s
c
ri
p
t
in
p
ro
p
ra
n
o
lo
l
g
ro
u
p
.
Y
e
h
u
d
a
e
t
a
l.
2
0
1
0
H
y
d
ro
c
o
rt
is
o
n
e
V
e
te
ra
n
,
m
a
le
,
N

2
C
o
n
tr
o
lle
d
c
a
s
e
s
tu
d
y
;
3
0
m
g
h
y
d
ro
c
o
rt
is
o
n
e
o
r
p
la
c
e
b
o
3
0
m
in
u
te
s
p
ri
o
r
to
8
p
ro
lo
n
g
e
d
e
x
p
o
s
u
re
s
e
s
si
o
n
s
P
ro
lo
n
g
e
d
e
x
p
o
s
u
re
;
im
a
g
in
a
l
e
x
p
o
s
u
re
(6
0
m
in
u
te
s
)
&
e
x
p
o
s
u
re
in
v
iv
o
;
h
o
m
e
w
o
rk
a
s
s
ig
n
m
e
n
ts
;
2
p
s
yc
h
o
-
e
d
u
c
a
ti
o
n
a
n
d
8
e
x
p
o
s
u
re
s
e
s
si
o
n
s
.
P
re
tr
e
a
tm
e
n
t:
H
y
d
ro
c
o
rt
is
o
n
e
:
9
7
.0
P
la
c
e
b
o
:
9
4
.0
P
o
st
tr
e
a
tm
e
n
t:
H
y
d
ro
c
o
rt
is
o
n
e
:
4
3
.0
P
la
c
e
b
o
:
5
2
.0
S
e
lf
-r
e
p
o
rt
(P
S
S
-S
R
):
m
o
re
s
y
m
p
to
m
d
e
c
lin
e
in
h
y
d
ro
c
o
rt
is
o
n
e
tr
e
a
te
d
th
a
n
p
la
c
e
b
o
tr
e
a
te
d
p
a
ti
e
n
t.
S
u
ri
s
e
t
a
l.
2
0
1
0
H
y
d
ro
c
o
rt
is
o
n
e
V
e
te
ra
n
,
m
a
le
,
N

2
0
R
C
T;
4
m
g
/k
g
h
y
d
ro
c
o
rt
is
o
n
e
o
r
p
la
c
e
b
o
im
m
e
d
ia
te
ly
a
ft
e
r
1
m
e
m
o
ry
re
a
c
ti
v
a
ti
o
n
s
e
s
si
o
n
Tr
a
u
m
a
ti
c
m
e
m
o
ry
re
a
c
ti
v
a
ti
o
n
;
w
ri
tt
e
n
a
c
c
o
u
n
t
o
f
2
‘‘w
o
rs
t’’
tr
a
u
m
a
ti
c
m
e
m
o
ri
e
s
;
1
s
e
s
si
o
n
.
N
/A
S
e
lf
-r
e
p
o
rt
(I
E
S
-R
):
lo
w
e
r
a
v
o
id
a
n
c
e
/
n
u
m
b
in
g
s
y
m
p
to
m
s
in
th
e
h
y
d
ro
c
o
rt
is
o
n
e
g
ro
u
p
c
o
m
p
a
re
d
to
p
la
c
e
b
o
.
B
ru
n
e
t
e
t
a
l.
2
0
1
1
P
ro
p
ra
n
o
lo
l
C
iv
ili
a
n
,
6
8
%
w
o
m
e
n
,
m
ix
e
d
tr
a
u
m
a
,
N

2
8
O
p
e
n
la
b
e
l;
0
.6
7
m
g
/k
g
s
h
o
rt
-a
c
ti
n
g

1
m
g
/k
g
lo
n
g
-a
c
ti
n
g
p
ro
p
ra
n
o
lo
l
(m
o
d
a
l
d
o
s
e
re
s
p
.
4
0
a
n
d
6
0
m
g
),
9
0
m
in
u
te
s
p
ri
o
r
to
6
s
e
s
si
o
n
s
Tr
a
u
m
a
ti
c
m
e
m
o
ry
re
a
c
ti
v
a
ti
o
n
;
re
a
d
in
g
a
lo
u
d
a
w
ri
tt
e
n
a
c
c
o
u
n
t
o
f
th
e
in
d
e
x
tr
a
u
m
a
(B
1
5
2
0
m
in
u
te
s
);
6
s
e
s
si
o
n
s
.
P
re
tr
e
a
tm
e
n
t:
P
ro
p
ra
n
o
lo
l:
7
1
.8
P
o
st
tr
e
a
tm
e
n
t:
P
ro
p
ra
n
o
lo
l:
4
5
.8
S
e
lf
-r
e
p
o
rt
(P
C
L
):
d
e
c
lin
e
o
f
s
e
lf
-r
e
p
o
rt
e
d
P
T
S
D
s
y
m
p
to
m
s
.
P
ro
p
ra
n
o
lo
l
C
iv
ili
a
n
,
7
1
%
w
o
m
e
n
,
m
ix
e
d
tr
a
u
m
a
,
N

7
O
p
e
n
la
b
e
l;
4
0
m
g
s
h
o
rt
-
a
c
ti
n
g

8
0
m
g
lo
n
g
-
a
c
ti
n
g
(L
A
)
p
ro
p
ra
n
o
lo
l,
9
0
m
in
u
te
s
p
ri
o
r
to
6
s
e
s
s
io
n
s
Tr
a
u
m
a
ti
c
m
e
m
o
ry
re
a
c
ti
v
a
ti
o
n
;
re
n
a
rr
a
ti
n
g
a
n
o
ra
l
a
c
c
o
u
n
t
o
f
th
e
in
d
e
x
tr
a
u
m
a
(B
1
5
2
0
m
in
u
te
s
);
6
s
e
s
si
o
n
s
.
P
re
tr
e
a
tm
e
n
t:
P
ro
p
ra
n
o
lo
l:
6
8
.4
P
o
st
tr
e
a
tm
e
n
t:
P
ro
p
ra
n
o
lo
l:
3
5
.6
Rianne A. de Kleine et al.
4
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2013, 4: 21626 - http://dx.doi.org/10.3402/ejpt.v4i0.21626
declined over time. Clinician Administered PTSD Scale
(CAPS) scores dropped on average with 28 (DCS) and
20 (Placebo) points from pre- to posttreatment. Looking
at treatment response, an effect in favor of DCS was
found. In the intent-to-treat sample, 64% in the DCS
group showed response [defined as a minimum of 10
points decrease on CAPS scores (Schnurr et al., 2007)],
compared to 38% in the placebo group. In the com-
pleters group, these numbers were overall higher, but
still favored DCS (88% versus 62%). What is more,
de Kleine et al. found that a large proportion of patients
(approximately 40%) could be considered early comple-
ters, i.e., those patients could end treatment before the
eighth session because of remission. When comparing
these early completers to those that needed all treatment
sessions (regular completers), an interesting difference
emerged. For the early completers, no difference between
those who received DCS and those who received placebo
was found. In contrast, for the regular completers, those
who received DCS showed better treatment outcome
(30 point CAPS decline) than those who received placebo
(6 point CAPS decline). The two subgroups (early vs.
regular completers) did not differ on baseline character-
istics as trauma type or comorbidity, but regular com-
pleters had more PTSD symptoms on baseline compared
to early completers. Based on these findings, the authors
tentatively concluded that DCS seems promising for
severe PTSD patients who do not initially respond to
exposure therapy.
However, a second study on DCS enhancement of
exposure therapy in PTSD patients showed different
outcome. Litz and colleagues (2012) examined the bene-
ficial effects of DCS in a male, veteran population.
Twenty-six participants were randomized to receive either
DCS (50 mg; N13) or placebo (N13) 30 minutes prior
to four imaginal exposure sessions. Litz and colleagues
found that the placebo group had better outcome than the
DCS group on both self-reported and clinician assessed
PTSD symptoms. On average, CAPS scores declined 20
points in the placebo condition, but increased with
2 points in the DCS condition. For treatment response
(10 points decrease on CAPS scores; Schnurr et al.,
2007), a similar pattern was found, 70% response in the
placebo condition and only 30% in the DCS condition.
Dosing, administration, adverse effects and
contra-indications for DCS enhancement
DCS was originally approved by the U.S. Food and Drug
Administration as an antibiotic for the treatment of
tuberculosis. Generally, it is dosed at 5001,000 mg twice
daily. Peak blood levels occur within 48 hours after oral
dosing, with a half-life time of 10 hours (Hardman &
Limbird, 2001). As an enhancer to exposure therapy,
DCS is single dosed before exposure sessions in low doses
(in both PTSD trials 50 mg). Dosage, dose timing orT
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number of doses have varied and were not significantly
related to outcome in DCS enhancement trials across
anxiety disorders (Bontempo et al., 2012).
DCS is orally taken and usually well tolerated. There is
no need to physically monitor patients after DCS intake.
Adverse reactions seem to be related to higher dosages of
the drug (i.e., more than 500 mg daily). Side effects that
have been observed in these high dosages involve nervous
system symptoms (e.g., convulsions, drowsiness, head-
ache, tremor), cardiovascular problems, allergy, and skin
rash. However, no serious adverse event was reported in
the PTSD trials or in any other clinical trial with DCS as
enhancer of exposure therapy (and thus with much lower
dosages).
Looking at contra-indications for DCS enhancement,
patients with (a history of) epileptic seizures or concur-
rent alcohol dependence or abuse were excluded from
participation in the PTSD trials, because of the risk
of epileptic episodes with DCS administration (again,
especially in higher doses), which is increased with
alcohol. Patients who used antidepressants were not
excluded in both PTSD trials, but they were required to
be on a stable dose prior to enrollment. In lab-rats it
was found that DCS did not facilitate extinction learn-
ing in rats previously exposed to the tricyclic antidepres-
sant imipramine (Werner-Seidler & Richardson, 2007),
but no evidence was found for negative interaction effects
between antidepressant medication and DCS enhance-
ment effects in patients with PTSD (de Kleine et al.,
2012) or other anxiety disorders (Hofmann et al., 2006;
Kushner et al., 2007; Storch et al., 2007).
Discussion
Granted that DCS was found to enhance exposure
therapy across anxiety disorders (Bontempo et al., 2012;
Norberg et al., 2008), so far findings in PTSD populations
are inconclusive. It is difficult to combine the findings
of the De Kleine et al. and Litz et al. studies, because
the studies differed largely with respect to population
(e.g., civilian vs. veteran) and methodology (e.g., different
lengths of treatment protocol and varying times of DCS
administration). In line with the findings of de Kleine
and colleagues (2012), there is some evidence that DCS
is especially beneficial in severely disordered patients
(Guastella, Dadds, Lovibond, Mitchell, & Richardson,
2007; Siegmund et al., 2011).
The proposition that DCS enhances consolidation
of extinction learning suggests that in case of within
session extinction (i.e., good extinction) DCS has bene-
ficial effects, but also that in absence of within session
extinction (i.e., no extinction), DCS might have undesir-
able effects by consolidation of the fear memory. Indeed,
Smits and colleagues (2013) found in an acrophobic
sample that DCS was superior to placebo in sessions
wherein within session extinction occurred but lead to
detrimental effects in sessions without extinction. Like-
wise, in PTSD patients, Litz et al. (2012) found indicators
that those who received DCS showed less within session
extinction compared to those who received placebo, and
Litz and colleagues suggest that this may be underlying
their finding that placebo outperformed DCS.
This raises the questions whether DCS could not be
better administered postsession and only when good
extinction learning took place. In animal studies, it was
found that postextinction training administration of
DCS could also enhance extinction effects (Ledgerwood,
Richardson, & Cranney, 2003). But, the first trials in
humans failed to find beneficial effects of postsession
administered DCS (Tart et al., 2013), except in those
patients who showed good within session habituation
(Smits et al., 2013). And, despite the apparent logic of
administering DCS only after successful sessions, re-
search on the predictive value of within session extinction
for overall treatment outcome is indecisive (Craske et al.,
2008; van Minnen & Hagenaars, 2002), and the question
what exactly defines a successful exposure session has
yet to be answered.
Reflecting on the clinical utility of DCS, it seems
a good candidate to implement in routine clinical care.
All in all, DCS seems safe, usually well tolerated and easy
to administer in routine clinical care settings. There are
no major drug specific contra-indications, although,
given the high incidence of alcohol abuse in PTSD popu-
lations (Mills, Teesson, Ross, & Peters, 2006), extra
attention should be given to alcohol use during DCS
enhanced exposure therapy.
MDMA
Proposed working mechanism of MDMA
enhancement
MDMA (93,4-methylenedioxymethamphetamine) is a
substituted phenetylamine and binds and reverses
monoamine transporters, resulting in serotonin release
and activation of the 5-HT receptor, and to a lesser
extent to the release of norepinephrine and dopamine
(Johansen & Krebs, 2009; Sessa, 2008). MDMA is
known in the public domain as the recreational drug
ecstasy. The drug has profound subjective effects as
feelings of euphoria and well-being, heightened senses,
and closeness to others (Cami et al., 2000; Kolbrich
et al., 2008). Johansen and Krebs (2009) suggested that
MDMA could enhance extinction learning via three
different mechanisms. First, MDMA might enhance
extinction learning via increased activity in the ventro-
medial prefrontal cortical (vmPFC) and decreased
amygdala activity; two interconnected brain regions
that have been found to be critical for extinction
learning (Phelps, Delgado, Nearing, & LeDoux, 2004).
Second, MDMA might enhance extinction learning via
Rianne A. de Kleine et al.
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enhanced cortisol and norepinephrine levels. And a
third, more indirect way, may be that MDMA increases
oxytocin levels, which may strengthen the therapeutic
alliance, and thereby facilitate extinction learning.
To date, no experimental study examined whether
MDMA could enhance extinction learning. There is
circumstantial evidence for the hypothesis that MDMA
strengthens the therapeutic alliance via enhanced oxyto-
cin release. In both animal (Thompson, Callaghan,
Hunt, Cornish, & McGregor, 2007) and human studies
(Dumont et al., 2009; Hysek, Domes, & Liechti, 2012)
it was found that MDMA leads to higher blood oxytocin
levels, and in humans it was shown that blood oxytocin
levels were strongly and positively correlated to subjective
pro-social feelings.
MDMA enhancement of exposure-based treatment
in PTSD patients
Three studies examined the augmentation effects of
MDMA of exposure-based treatment in PTSD patients.
Bouso and colleagues (2008) planned to examine the bene-
ficial effects of MDMA paired with psychological treat-
ment in 29 patients with chronic PTSD following sexual
assault, who had failed to respond to previous treat-
ment. But due to political pressure, they were forced to
close their double-blind randomized placebo-controlled
trial after including only six participants and no results
are available.
In the first completed study, Mithoefer and colleagues
(2011) examined MDMA assisted treatment in 20 PTSD
patients. All patients had not responded to previous
psychotherapy or medication. Participants were rando-
mized to receive either MDMA (125 mg, with the pos-
sibility of a supplemental dose of 62.5 mg; N12) or pill
placebo (N8) adjunctive to two 810 hour individual
psychotherapy sessions. Prior to the enhanced session,
participants engaged in two sessions aimed at establishing
a therapeutic alliance. As described in the treatment
manual (available from www.maps.org), the enhanced
sessions had a non-directive character: participants were
instructed to close their eyes, relax (with the help of music)
and allow the inner experience to unfold. Exposure to
the traumatic experience occurred spontaneously. After
each MDMA enhanced session, four integration sessions
took place focusing on discussion of the experiences in the
experimental sessions and further emotional processing
of the traumatic experience. MDMA enhanced therapy
outperformed placebo enhanced therapy on both clinician
rated and self-reported PTSD symptoms. On average,
CAPS scores in the MDMA group decreased 50 points
from pre- to posttreatment, compared to 13 points in the
placebo group. Further, over 80% of participants in the
MDMA group (10 out of 12 patients) lost their PTSD
diagnosis, compared to 25% (two out of eight patients) in
the placebo group. The double-blind phase of the study
was followed up by a cross-over open-label phase, so that
in the end 19 participants received two or three MDMA
enhanced treatment sessions. Long-term follow-up on 16
participants showed that for 14 of them, benefits lasted
over time (Mithoefer et al., 2013). All in all, these appeared
to be very promising findings. However, some important
methodological limitations require noting. First, due to
the profound effects of MDMA compared to pill placebo,
it was impossible to keep participants and therapists
blind to treatment condition. Second, participants in the
MDMA group received more supplementary (exposure)
sessions after the experimental sessions than participants
in the placebo group. Third, the psychotherapy component
was not an empirically supported treatment delivered in a
standard manner.
In the most recent pilot study (Oehen, Traber, Widmer,
& Schnyder, 2013), 12 treatment refractory PTSD pa-
tients were randomly allocated to receive either MDMA
(125 and 62.5 mg 2.5 hours later; N8) or active placebo
(25 and 12.5 mg 2.5 hours later; N4) supplementary to
three 8-hour individual psychotherapy sessions. Oehen
et al. used roughly the same study protocol as Mithoefer
and colleagues and exactly the same treatment protocol.
However, the results of this study were less profound in
favoring MDMA over placebo. There was a significant
interaction of group by time for self-reported PTSD
symptoms in favor of MDMA, and a trend towards
better outcome for the MDMA group in clinician rated
scores (p0.066). But, compared to the Mithoefer study,
change in CAPS scores from baseline to posttreatment
was small (16 points decrease in the MDMA group and
3 points increase in the placebo group), and, notably, all
participants still fulfilled PTSD diagnostic criteria at
posttreatment.
Dosing, administration, adverse effects and
contra-indications for MDMA enhancement
A typical (recreational or therapeutic) dose of MDMA is
125 mg, and was also used in the PTSD studies. It is orally
administered and comes in the form of tablets, capsules
or powder. MDMA is detectable in the blood within 30
minutes after intake, peak blood levels are 12 hours after
intake and MDMA has a half-life of about 68 hours
(Green, Mechan, Elliott, O’Shea, & Colado, 2003).
Acute adverse effects are commonly reported, includ-
ing jaw clenching, grinding of the teeth, nausea, tremor
and feelings of tension and anxiety (Kolbrich et al.,
2008). After MDMA usage, there is a period of neuro-
chemical recovery characterized by anhedonia, lethargy
and depression. Acute adverse effects were indeed reported
in the PTSD trials, but there were no serious adverse
events. Further, neurotoxicity has been demonstrated in
animals, and suggested in humans, but functional impair-
ment in humans has not been convincingly related to
MDMA (Dumont & Verkes, 2006). Importantly, not all
Exposure enhancement in PTSD patients
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neuropharmocological actions of MDMA are well com-
prehended (Green, Marsden, & Fone, 2008).
The cardiovascular effects of the drug are important to
note. MDMA leads to higher blood pressure and elevated
heart rates (Dumont & Verkes, 2006). Thus, MDMA is
unsuitable for PTSD patients with cardiovascular pro-
blems, requires physical examination before administra-
tion (stress-electrocardiogram), and physical monitoring
and the presence of a physician during MDMA enhanced
treatment sessions. Further, in the PTSD trials, partici-
pants were required to taper all psychotropic medica-
tion prior to enrollment. Interestingly, empirical data
suggests that medication that inhibits serotonin (5-HT)
and norepinephrine (NE) uptake (respectively SSRI’s and
SNRI’s), drugs commonly used by PTSD patients, attenu-
ate the effects of MDMA (Hysek et al., 2012; Liechti,
Baumann, Gamma, & Vollenweider, 2000).
Discussion
In conclusion, even though the initial findings of
MDMA enhancement appear promising, more controlled
studies on MDMA enhanced treatment are necessary to
draw reliable conclusions on the efficacy of this combined
treatment strategy. In the studies so far, MDMA was
not paired to a proven effective treatment strategy, i.e.,
prolonged exposure (Foa & Rothbaum, 1998). Critically
reflecting on the treatment manual used in MDMA trials,
it is questionable whether the non-directive, explorative
intervention should be considered exposure, as it diverges
from evidence-based exposure treatments such as PE.
Preferably, new trials would combine MDMA with those
established exposure treatments.
With respect to one of the proposed working mechan-
isms of MDMA enhancement, that it enhances extinction
learning indirectly via improvement of the therapeutic
alliance due to heightened oxytocin levels, the question
arises whether direct administration of oxytocin would
also enhance exposure therapy. Olff and colleagues (2010)
suggest that it might, and may even be more powerful
than MDMA. Currently, Olff’s group is examining oxy-
tocin enhancement of exposure therapy in refugees
suffering from PTSD.
Reflecting on the feasibility of MDMA enhancement,
all together there are questions regarding safety and
tolerability. Considering the high rate of comorbid depres-
sion in PTSD patients (Kessler et al., 2005), the negative
mood effects post-MDMA intake calls for caution.
Further, a substantial proportion of PTSD patients
use SSRI’s or SNRI’s which appear to be incompatible
with MDMA enhancement. Implementation in routine
clinical care is further complicated by the need for physical
monitoring during MDMA enhancement, especially with
its known cardiac effects. And notably, the use of MDMA
as an adjunctive to treatment is not without controversy,
as its use as a recreational drug (‘‘ecstasy’’) is criminalized
in most countries. The alternative of oxytocin enhance-
ment may have better clinical utility, considering that
it is easily administered e.g., as a nasal spray and produces
little adverse effects (MacDonald et al., 2011).
Hydrocortisone
Proposed working mechanism
Hydrocortisone is a synthetic glucocorticoide that mim-
ics the effects of cortisol. In situations of stress, the
hypothalamuspituitaryadrenal (HPA) axis is activated,
which results in the release of glucocorticoide hormones,
i.e., cortisol. It is well-established that cortisol has
(complex) effects on learning and memory (see for a
review on glucocorticoide: de Quervain, Aerni, Schelling,
& Roozendaal, 2009). First, glucocorticoids play a role
in the consolidation of extinction learning. It has been
shown that administration of glucorticoids facilitates
consolidation of extinction learning, while suppression
of glucorticoid function impairs extinction learning.
Second, glucorticoids impair the retrieval of emotional
memory. In PTSD patients it was found that low-dose
cortisol administration as stand-alone treatment resulted
in reduction of re-experiencing symptoms, i.e., unwanted
retrieval of emotional memories (Aerni et al., 2004).
Enhancement of exposure therapy with hydrocortisone
could be beneficial via both mechanisms: (1) enhanced
consolidation of extinction learning, and (2) inhibition
of emotional memory retrieval. The latter may reduce
distress after exposure sessions, because retrieval of the
emotionally disturbing traumatic memory that was tar-
geted during an exposure session is inhibited (Yehuda,
Bierer, Pratchett, & Malowney, 2010).
Two randomized studies provided support for exposure
augmentation with hydrocortisone in anxiety-disordered
patients. Hydrocortisone given prior to exposure sessions
proved to augment treatment effects in patients suffering
from spider phobia (Soravia et al., 2006) and acrophobia
(de Quervain et al., 2011).
Hydrocortisone enhancement of exposure-based
treatment in PTSD patients
To date, there are no randomized clinical trials on the
augmentation effects of exposure therapy with hydrocor-
tisone in PTSD patients. Two large scaled clinical studies
by Yehuda and colleagues are currently including partici-
pants (Clinicaltrials.gov identifiers NCT01525680 and
NCT01090518). Grounding their upcoming trials, Yehuda
and colleagues (2010) published a case study on hydro-
cortisone enhancement in two male veterans suffering
from severe PTSD and comorbid depressive disorder.
Participants were treated with PE therapy and either
hydrocortisone (30 mg, oral, 30 minutes prior to exposure
session 310) or placebo (following the same time sche-
dule). The patient who received hydrocortisone improved
Rianne A. de Kleine et al.
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more over the course of treatment than the patient who
received placebo (54 versus 40 points reduction on CAPS),
specifically with respect to avoidance symptoms.
In an experimental design, Suris and colleagues (2010)
investigated the effects of hydrocortisone in 20 male
veterans suffering from PTSD. Participants received
either hydrocortisone (intravenous, 4 mg/kg) or placebo,
directly after one exposure-based session. During this
session, participants wrote a description of their two most
traumatic events and identified from a list bodily sensa-
tions they experienced during these events. Afterwards,
a member of the research team composed a 30-second
script portraying each event. A week later, scripts were
presented to participants while physiological responses
(heart rate, skin conductance and corrugator and frontalis
muscle electromyogram) were measured. Subsequently,
they filled out questionnaires on PTSD and depressive
symptoms. Suris et al. found that, compared to placebo,
participants who received hydrocortisone had lower self-
reported PTSD avoidance and numbing symptoms at
script presentation. There were no significant differences
on any other PTSD symptom cluster or on the physiolo-
gical measures. Also, at the 1 month follow-up assess-
ment, no group differences on any outcome were found.
In the discussion section of their article, the authors list
several limitations of their study. Besides the low power,
they critically reflect on their study design, and suggest
that with a higher dose and more enhanced treatment
sessions effects may have been larger and more lasting.
Dosing, administration, adverse effects and contra-
indications for hydrocortisone enhancement
Hydrocortisone can be administered orally, intramuscu-
larly or intravenously. It is used in the treatment of
inflammation disease, e.g., severe allergies, arthritis or
asthma, and as a replacement strategy in the chronic
endocrine disorder Addison’s disease. Therapeutic doses
vary between 20 and 500 mg daily, depending on the
specific disease treated. Hydrocortisone is well absorbed
after oral administration, achieving peak blood concen-
trations after 1 hour, with a half-life of approximately
1.5 hours. Dosing and administration of hydrocortisone
given in supplementary fashion to exposure-based treat-
ment in PTSD patients have varied largely [eight times,
60 minutes prior to exposure, orally 30 mg (Yehuda
et al., 2010) versus one time, immediately after exposure,
intravenously 4 mg/kg (Suris, North, Adinoff, Powell,
& Greene, 2010)]. In the two non-PTSD exposure
enhancement trials, hydrocortisone was given three or
four times, 60 minutes prior to exposure, orally and dosed
at 10 and 20 mg (de Quervain et al., 2011; Soravia et al.,
2006).
Low doses of hydrocortisone (e.g., 1030 mg once
a week) do not cause major side effects, nor do they
suppress endogenous cortisol levels (de Quervain et al.,
2009). There is no need to physically monitor patients
after hydrocortisone intake. Besides the regular exclusion
criteria for drug trials (e.g., pregnancy, severe medical
illness or drug-hypersensitivity) there appear to be no
major drug specific exclusion criteria for hydrocortisone
enhanced treatment relevant to the PTSD population.
While participants who used psychotropic medication
were excluded from non-PTSD trials (de Quervain et al.,
2011; Soravia et al., 2006), in upcoming PTSD trials
participants with (stable) psychotropic medication are
included.
Discussion
The evidence for beneficial effects of hydrocortisone
enhancement of exposure therapy in PTSD patients is
very limited. Efficacy studies in other anxiety disorders
showed augmentation of exposure effects, but upcoming
controlled trials will have to show whether this gener-
alizes to PTSD patients.
In PTSD patients, it appears that hydrocortisone
specifically affects avoidance symptoms. Avoidance has
been implicated in the development and maintenance of
PTSD (Foa, Hembree, & Rothbaum, 2007). Hypotheti-
cally, decline of avoidance symptoms over the course
of treatment could improve compliance with exposure
sessions and in that way hasten or improve beneficial
treatment effects (Yehuda et al., 2010). Further, it is of
interest to note that hydrocortisone may have acute
anxiolytic effects. A clinical trial in patients with social
phobia showed that hydrocortisone (25 mg) given 1 hour
prior to an exposure task reduced self-reported fear
(Soravia et al., 2006). What the effect is of presession
hydrocortisone on fear levels during exposure therapy in
PTSD patients, and if and how this influences treatment
efficacy, has yet to be established. The proposition that
hydrocortisone impairs retrieval of the traumatic memory
targeted during an exposure session may reduce postexpo-
sure distress and enhance treatment acceptability. Given
the high incidence of (early) exposure treatment dropout
(Bisson & Andrew, 2007), improving treatment accept-
ability is of great relevance.
Reflecting on its clinical utility, hydrocortisone seems
safe, well tolerated and easy to administer. There are
no major drug specific exclusion criteria relevant to the
PTSD population. So, albeit premature, hydrocortisone
appears to be feasible to implement in routine clinical
care.
Propranolol
Proposed working mechanism
Propranolol is a synthetic b-adrenergic receptor blocker
that crosses the blood brain barrier and has both
peripheral noradrenergic effects and central inhibitory
effects on protein synthesis. Protein synthesis is necessary
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to (re)consolidate new memories and a protein synthesis
inhibitor, such as propranolol, could interfere with this
process (Davis & Squire, 1984). Indeed, experimental
studies in non-clinical samples demonstrated that pro-
pranolol has effects on memory reconsolidation (see
for overview: Lonergan, Olivera-Figueroa, Pitman, &
Brunet, 2012). For instance, Kindt and colleagues (2009)
found that disruption of reconsolidation by oral admin-
istration of propranolol resulted in diminished fear
responses to conditioned stimuli. Even though there is
growing interest in (disruption of) reconsolidation pro-
cesses, clinical studies in anxiety-disordered patients are
limited to a couple of studies in PTSD patients.
Propranolol enhancement of exposure-based
treatment in PTSD patients
In a randomized clinical trial, Brunet and colleagues
(2008) examined the effects of propranolol given directly
after one exposure-based session in 19 chronic PTSD
patients following mixed trauma. Participants received
either propranolol (40 mg short acting (SA) and 2 hours
later 60 mg long acting (LA); N9) or identical looking
placebo (following the same time schedule; N10)
immediately after an exposure-based session. During
this 20-minute session, participants described, in writing
on a standard script preparation form, two events that
caused their PTSD and provided details on request.
Afterwards, a member of the research team composed
and recorded a 30-second during script portraying each
event. A week later, participants were exposed to the
trauma scripts while physiological responses (heart rate,
skin conductance and left corrugators electromyogram,
i.e., facial frowning muscle) were measured. Participants
who had received propranolol postsession responded
with lower heart rate and skin conductance than parti-
cipants who had received placebo. Unfortunately, infor-
mation on long-term effects, i.e., PTSD symptoms was
not included so there is no information regarding the
maintenance of these effects and if there was any effect on
PTSD symptoms.
There is support for the efficacy of propranolol as a
treatment enhancement strategy from three open-label
studies by Brunet and colleagues (2011). In the first study,
28 patients with chronic PTSD following mixed trauma
received six propranolol enhanced exposure-based treat-
ment sessions. Ninety minutes prior to the first session
participants received 0.69 mg/kg SA propranolol, after 90
minutes they received a subsequent dose of 1 mg/kg LA
propranolol. In this first session, they provided a written
account of the traumatic event leading to their PTSD. In
the subsequent enhanced treatment sessions, participants
received both SA and LA propranolol 90 minutes prior to
the start of the session and read aloud their traumatic
account to an interviewer, as if the event was happening
in the here and now. Sessions lasted approximately 1520
minutes. At posttreatment, PTSD symptoms were sig-
nificantly lower than at pretreatment (mean CAPS
decline from pre- to posttreatment of 26 points) and 20
participants (71%) no longer met the criteria for PTSD.
In the second open study, a similar protocol was
followed, only now participants provided an oral instead
of a written account of the index trauma and propranolol
was given in fixed doses of 40 mg SA and 80 mg LA.
Participants were seven chronic PTSD sufferers with
mixed-trauma history. Again, there was a significant
drop in PTSD symptoms (mean CAPS scores: 68 at
baseline and 36 posttreatment). Comparable to the first
study, 71% (five participants) no longer met PTSD
diagnostic criteria. In study 3, 32 participants self-
selected to receive propranolol enhanced treatment
(N7) or no treatment at all (N25). Participants all
suffered from PTSD following the September 2001
industrial disaster in Toulouse, France. The protocol
was similar to study 1 with slight differences in propra-
nolol dosing (see Table 1) and there was no administra-
tion of CAPS interviews. In line with the previous
findings, for those participants who received propranolol
enhanced treatment, self-reported PTSD symptoms de-
clined over time. Six out of seven treated participants
(86%) lost their PTSD diagnosis, compared to only two
out of 25 (8%) in the control group.
Dosing, administration, adverse effects and contra-
indications for propranolol enhancement
Propranolol lowers heart rate and relaxes blood vessels
to improve blood flow and decrease blood pressure.
As such, it is used for treatment of hypertension, angina
pectoris, migraine and tremor. In addition, propranolol
has anxiolytic effects (it reduces physical anxiety symp-
toms such as trembling and heart pounding) and is used
to reduce performance related anxiety. Generally, doses
vary between 40 and 240 mg daily, depending on treat-
ment condition. In PTSD trials, propranolol was single
dosed directly before or after exposure-based treatment
session(s) with doses varying between 80 and 120 mg.
Propranolol is rapidly absorbed. For SA propranolol,
peak blood levels occur within 12 hours after ingestion
and half-life is approximately 36 hours, while for LA
propranolol this is respectively 5 hours and between 10
and 20 hours.
Adverse reactions to propranolol appear to be dose
related and include light headedness, weakness, fatigue,
bradycardia, congestive heart failure, hypotension, nau-
sea and vomiting. In PTSD patients, when given as
a treatment enhancer, no serious adverse events were
reported and side effects were restricted to mild sedation
(Brunet et al., 2011).
Propranolol is orally administered. Because proprano-
lol lowers blood pressure, in the Brunet trials blood
pressure was monitored after the first propranolol intake.
Rianne A. de Kleine et al.
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If systolic blood pressure levels did not drop below a
certain point (100 mmHg), participants received the
subsequent doses. Because of its cardiovascular effects,
people with low blood pressure, a (family) history of
cardiac problems (e.g., heart failure, heart block or
certain cardiac arrhythmias) were excluded from par-
ticipation in propranolol studies. Like propranolol,
alcohol relaxes blood vessels, and simultaneous use
may cause problems. In the open-label trials, participants
who used medication that could involve dangerous
interactions with propranolol were excluded from parti-
cipation. Notably, this includes antidepressants that
are cytochrome P450 2D6 inhibitors, such as the SSRI
paroxetine.
Discussion
Combined, the findings with propranolol enhancement
are promising and we await a placebo-controlled rando-
mized clinical trial on propranolol enhancement in PTSD
patients. However, due to the uncontrolled methodology
of the propranolol treatment enhancement studies, the
question of whether the observed benefits were a con-
sequence of propranolol enhancement or the psychologi-
cal intervention in itself remains unanswered.
Likewise, regarding the proposed working mechanism,
it is unclear from Brunet’s studies whether propranolol
blocked fear-memory reconsolidation or, alternatively,
enhanced extinction consolidation. Parsons & Ressler
(2013) question whether propranolol would succeed in
reconsolidation blockage in PTSD patients, based on
research findings that older memories are more difficult
to influence after retrieval (Milekic & Alberini, 2002)
and that repeated retrieval (i.e., re-experiences) can
strengthen fear memories and make them more resistant
to extinction and reconsolidation effects (Suzuki et al.,
2004). The upcoming controlled trial of Brunet’s group
(N50, six enhanced sessions with 40 mg SA/60 mg LA
propranolol, Clinicaltrials.gov identifier NCT01127568)
will provide us with more information on the potential of
propranolol as a treatment enhancer in PTSD patients.
Considering the feasibility of propranolol for exposure
treatment enhancement in PTSD patients, propranolol
appears to be well tolerated and easy to administer.
However, its cardiovascular effects require caution in
patients with (a family history) of cardiovascular pro-
blems, and alcohol use should be carefully monitored
during propranolol enhanced treatment, especially con-
sidering that alcohol abuse is a common problem in
PTSD patients (Mills et al., 2006). PTSD patients
who use SSRI’s have been excluded from propranolol
enhancement studies (and will be excluded in upcoming
trials, see www.clinicaltrials.gov), because of potential
dangerous drug-drug interactions. This may limit gen-
eralizability, considering that in routine clinical care
many PTSD patients receive psychotropic medication,
including SSRI’s, prior to the start of psychological
treatment. For instance, in a large randomized clinical
trial, over 75% of PTSD patients were receiving psycho-
tropic medication at baseline (Schnurr et al., 2007).
General discussion
In this article, we reviewed the clinical data on treat-
ment enhancement of exposure-based therapies in PTSD
patients. Enhancement of learning processes during
exposure therapy is an emerging research field and shows
promise in improving treatment efficacy for PTSD.
Reviewing the literature to date also revealed some
challenges for future research, discussed below.
Focusing on those enhancers that were given in
addition to exposure-based treatment sessions in patients
suffering from PTSD, resulted in the review of four
different pharmacological enhancers. The early stage of
exposure treatment enhancement studies is reflected in
the reviewed studies, which could largely be considered
pilot work. Only a few studies were randomized clinical
trials with adequate blinding and sample size [DCS:
De Kleine et al. (2012); Litz et al. (2012); MDMA: Oehen
et al. (2013)]. All studies differed from one another in
greater or lesser extent, so that, to date, no study has been
fully replicated. Further, the studies on MDMA were
supported by one association (MAPS, multidisciplinary
association of psychedelic studies) and the same research
group conducted all the studies on propranolol enhance-
ment. For most enhancers the empirical evidence is
still limited and conclusions on efficacy are premature.
Similarly, a conclusion about which enhancer has the
most potential to enhance exposure therapy effects in
PTSD patients cannot be drawn. To date, DCS has been
studied most and proven efficacious across anxiety
disorders, but results in PTSD studies were mixed, while
for the other enhancers efficacy studies are still scarce.
Even though all reviewed studies paired the pharmaco-
logical agent to an exposure-based treatment session,
studies varied widely in the nature and amount of ex-
posure, and only two studies paired the agent to a full
protocol of proven effective treatment strategy. De Kleine
and colleagues (2012) paired DCS with PE therapy (Foa &
Rothbaum, 1998), and Yehuda and colleagues (2010)
added hydrocortisone to PE therapy. This variation in
exposure dose is partly due to differences in proposed
working mechanisms, extinction consolidation enhance-
ment and/or reconsolidation blockage, which suggests
respectively longer and shorter duration of trauma mem-
ory exposure. Note however, that even though extinction
and reconsolidation are considered to be two distinct
processes, there is also some evidence of overlapping
properties (Parsons & Ressler, 2013), and it is not yet
perfectly understood how both processes contribute to
exposure therapy effects (Kindt & Soeter, 2013). We would
like to encourage future enhancement trials to pair the
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cognitive enhancer with an empirically based treatment
such as PE therapy. Only then it can be established whether
augmentation with cognitive enhancers is superior to
already proven effective treatment strategies. In this line,
we suggest that authors provide a detailed description of
the psychological intervention in their enhancement stu-
dies reports, so that readers may be able to understand
exactly what was administered and judge its quality and
propriety.
Almost all reviewed studies reported outcome on the
CAPS scores, which allowed us to compare studies on
symptom decline over time. In some studies, the decline
of CAPS scores was spectacular (]50 points; Mithoefer,
Wagner, Mithoefer, Jerome, & Doblin, 2011; Yehuda
et al., 2010), and well exceeded those of non-enhanced
exposure trials, but note that these enhancement studies
were less well controlled. In addition to reporting overall
CAPS scores, we would like to argue that future en-
hancement studies report scores for PTSD symptom
clusters (re-experiencing, hyperarousal and avoidance
symptoms) separately. The two reviewed studies on
hydrocortisone, showed that hydrocortisone appears to
be beneficial primarily via diminishment of avoidance
behavior. It would be interesting to learn whether en-
hancers differ in their effects on different symptom
clusters. This would provide us with more information
on possible mechanisms of action. Thinking about future
directions for this field, it would be interesting to explore
for which patients augmentation with a cognitive en-
hancer might be especially beneficial. Studies address-
ing individual differences (for instance: dissociative
subtype of PTSD (American Psychiatric Association,
2013), comorbidity, trauma type, personality features)
may enhance our understanding of treatment efficacy and
ultimately contribute to treatment matching strategies.
Reflecting on the clinical utility of the cognitive en-
hancers, with the exception of MDMA, they seem to be
safe and well tolerated. When used as a cognitive enhancer,
the doses of DCS, hydrocortisone, and propranolol
are relatively low and infrequent, while adverse effects
of these pharmacological agents have been related to
higher doses and frequent use. In this respect, they show
advantage over exposure enhancement with SSRI’s
(Schneier et al., 2012), with which adverse effects are
commonly reported. Given the high incidence of alcohol
abuse in PTSD patients (Mills et al., 2006), close moni-
toring of alcohol intake during enhanced exposure
treatment is advised. Although alcohol abuse is not
considered to be a contra-indication for exposure treat-
ment in PTSD patients (Mills et al., 2012; van Minnen,
Harned, Zoellner, & Mills, 2012) the potential hazardous
drug-drug interactions call for caution. Additionally,
the use of concurrent psychotropic medication, specifically
SSRI’s, deserves extra attention in the light of exposure
treatment enhancement. Considering that a large propor-
tion of PTSD patients receive psychotropic medication,
and that use of antidepressants (SSRI’s) is an exclusion
criterion for enhancement studies with propranolol
and MDMA, generalizability of findings with these
cognitive enhancers, and ultimately clinical utility, are
limited. Last, there is some data from DCS enhancement
showing that augmentation can also have detrimental
effects when sessions lack extinction. For safe use in clini-
cal care, it is important to gather more information on
potential undesirable outcomes. Therefore, we urge
authors to report symptom worsening in participants as
adverse effects and researchers to further investigate
process variables that affect outcome.
In the coming years the amount of studies in this
exciting new field will expand quickly. New enhancers
(yohimbine, oxytocin, methylene blue) will be studied, and
previously studied enhancers will be examined in larger
trials. A search in trial registries (www.clinicaltrials.gov;
www.clinicaltrialsregister.eu) reveals that large(r) clinical
trials on DCS (N100), hydrocortisone (N60), and
propranolol (N50) enhancement in PTSD patients are
currently enrolling patients. Hopefully, translational de-
signs will additionally provide us with more information
on the mechanisms of action of exposure therapy (extinc-
tion and reconsolidation) and the possibility to enhance
these processes with diverse pharmacological agents.
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